



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# بسم الله الرحمن الرحيم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم



# شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



### يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**MONA MAGHRABY**



# **Role of Urinary Intestinal Fatty Acid Binding Protein in Prediction of Necrotizing Enterocolitis and Its Correlation with GutCheck Score**

*Thesis*

*Submitted for Partial Fulfillment of  
Master Degree in Pediatrics*

*Presented By*

**Aya Abdelaziz Abdelkarim**

*M.B.B.Ch.*

*Faculty of Medicine, Ain Shams University*

*Under Supervision of*

**Prof. Dr. Ibrahim Saad Hassan Abu Saif**

*Professor of Pediatrics and Neonatology  
Faculty of Medicine, Ain Shams University*

**Dr. Wafaa Osman Ahmed**

*Lecturer of Pediatrics and Neonatology  
Faculty of Medicine, Ain Shams University*

**Dr. Walaa Ahmed Yousry Kabiell**

*Assistant Professor of Clinical Pathology  
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine  
Ain Shams University*

**2021**



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبَّحَانَكَ لَا يَعْلمُ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Ibrahim Saad Hassan Abu Saif**, Professor of Pediatrics - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Wafaa Osman Ahmed**, Assistant Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Walaa Ahmed Yousry Kabil**, Assistant Professor of Clinical pathology, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

*Last but not least my sincere thanks and appreciation to all patients participated in this study.*

**Aya Abdelaziz Abdelkarim**

# List of Contents

Title	Page No.
List of Tables.....	i
List of Figures.....	iii
List of Abbreviations.....	iv
Introduction .....	1
Aim of the Work.....	5
Review of Literature	
Necrotizing Enterocolitis (NEC) .....	6
Urinary Intestinal Fatty Acid Binding Protein.....	29
GutCheck <sup>NEC</sup> .....	38
Patients and Methods.....	48
Results.....	57
Discussion .....	77
Summary.....	96
Conclusion .....	101
Recommendations .....	102
References .....	103
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
<b>Table 1:</b>	Modified bells criteria for diagnosis of NEC .....	17
<b>Table 2:</b>	Complications of NEC .....	18
<b>Table 3:</b>	NEC treatment.....	24
<b>Table 4:</b>	GutCheckNEC risk index .....	46
<b>Table 5:</b>	Distribution of demographic data of the studied groups .....	57
<b>Table 6:</b>	Demographic data of the studied groups .....	58
<b>Table 7:</b>	Clinical and laboratory data of the studied groups. ....	59
<b>Table 8:</b>	Correlation between each risk factor and GutCheck <sup>NEC</sup> score:.....	61
<b>Table 9:</b>	Correlation of Initial and follow-up scores with other risk factors not included in the GutCheck <sup>NEC</sup> among cases .....	65
<b>Table 10:</b>	Comparison of Initial and follow-up scores among studied groups and paired t-test Comparison of Initial and follow-up scores among cases .....	66
<b>Table 11:</b>	Risk stratification according to GutCheck <sup>NEC</sup> for cases-controls: .....	68
<b>Table 12:</b>	Comparison of Initial and follow-up score among cases according to final Bells stage .....	70
<b>Table 13:</b>	Comparison of studied groups as regards marker level.....	70
<b>Table 14:</b>	Variables affecting marker level among cases.....	72
<b>Table 15:</b>	Variables affecting marker level among Controls .....	73



## List of Tables *cont...*

Table No.	Title	Page No.
<b>Table 16:</b>	Regression analysis of factors predicting marker .....	74
<b>Table 17:</b>	ROC Curve of the marker .....	74
<b>Table 18:</b>	ROC Curve of the marker .....	75

# List of Figures

Fig. No.	Title	Page No.
<b>Figure 1:</b>	TLR4 signaling .....	11
<b>Figure 2:</b>	Distribution of cases-controls according to gender.....	57
<b>Figure 3:</b>	Comparison of studied groups as regards blood culture, Blood transfusion and Inotropes .....	60
<b>Figure 4:</b>	Comparison between initial and follow-up score among studied groups with positive blood cultures.....	62
<b>Figure 5:</b>	Comparison between initial and follow-up score among studied groups with positive blood transfusion .....	63
<b>Figure 6:</b>	Comparison between initial and follow-up score among studied groups with metabolic acidosis .....	64
<b>Figure 7:</b>	Comparison of Initial and follow-up score among studied groups.....	67
<b>Figure 8:</b>	Risk stratification according to GutCheck NEC for cases-controls initially .....	68
<b>Figure 9:</b>	Risk stratification according to GutCheck NEC for cases-controls after 14 days .....	69
<b>Figure 10:</b>	Comparison of studied groups as regards marker level .....	71
<b>Figure 11:</b>	ROC curve of the marker.....	76

# List of Abbreviations

Abb.	Full term
<i>AUC</i> .....	<i>Area under curve.</i>
<i>CI</i> .....	<i>Confidence interval.</i>
<i>COX</i> .....	<i>Cyclo-oxygenase.</i>
<i>CpG</i> .....	<i>Cytosine phosphate guanine.</i>
<i>EGF</i> .....	<i>Epidermal growth factor.</i>
<i>ELISA</i> .....	<i>Enzyme-linked immunosorbent assay.</i>
<i>Fibrinogen-γ</i> .....	<i>Fibrinogen gamma.</i>
<i>GA</i> .....	<i>Gestational age.</i>
<i>GIT</i> .....	<i>Gastro-intestinal tract.</i>
<i>IAIP</i> .....	<i>Inter-Alpha Inhibitor Protein.</i>
<i>IL</i> .....	<i>Interleukin</i>
<i>kDa</i> .....	<i>Kilodalton.</i>
<i>MV</i> .....	<i>Mechanica ventilator.</i>
<i>NCPAP</i> .....	<i>Nasal continuous positive airway pressure.</i>
<i>NEC</i> .....	<i>Necrotizing enterocolitis.</i>
<i>ng/ml</i> .....	<i>Nannogram per millimeter.</i>
<i>NICU</i> .....	<i>Neonatal intensive care unit.</i>
<i>NPO</i> .....	<i>Nil per os (nothing by mouth)</i>
<i>OR</i> .....	<i>Odds ratio</i>
<i>PDA</i> .....	<i>Patent ductus arteriosus.</i>
<i>rhEPO</i> .....	<i>Recombinant human erythropoietin.</i>
<i>rhG-CS</i> .....	<i>Recombinant human granulocyte colony-stimulating factor.</i>
<i>ROC</i> .....	<i>Receiver operating curve.</i>
<i>RPM</i> .....	<i>Round per minute.</i>
<i>SIP</i> .....	<i>Spontaneous intestinal perforation.</i>
<i>TGF</i> .....	<i>Tissue growth factor.</i>
<i>TNFα</i> .....	<i>Tumor necrosis factor alpha</i>
<i>u-IFAB</i> .....	<i>Urinary intestinal fatty acid binding protein</i>
<i>VLBW</i> .....	<i>Very low birth weight.</i>

## INTRODUCTION

Necrotizing enterocolitis (NEC) is a severe devastating inflammatory condition affecting the gastrointestinal tract of neonates especially preterm babies, it is the most common GIT emergency in preterm babies with high morbidity and mortality.

The definite etiology of NEC is still not completely understood, However it is strongly associated with gut hypoxia-ischemia and increased bacterial colonization and translocation in the immature gut, thus the most important risk factors are prematurity, low gestational age, hemodynamic instability leading to gut ischemia caused by large patent ductus arteriosus (PDA) or congenital heart disease and sepsis (*Gephart et al., 2014*).

Early manifestations of NEC are usually subtle resembling sepsis (temperature instability, hypotension, bradycardia or tachycardia) even though it can turn into severe disease leading to intestinal gangrene without implementing early management plan including gastric decompression, withholding feeding and aggressive antibiotic therapy (*Gephart and Hanson, 2017*).

It affects 7 of each 100 neonate admitted in NICUs worldwide with high mortality reaching up to 100% in late cases (*Ginglen and Butki, 2020*).

Mortality rate in NEC ranges from 10% to more than 50% in infants who weigh less than 1500 g, depending on the severity of disease, compared with a mortality rate of 0-20% in babies who weigh more than 2500 g. Extremely premature infants (1000 g) are still particularly vulnerable, with reported mortality rates of 40-100%. It ranges from 4.7% in term infants and 11.9% in premature babies (*Wiswell et al., 1988*).

Early diagnosis of NEC plays a fundamental role in management and improves outcome, However it remains challenging due to lack of confidential laboratory biomarkers that can detect NEC before the appearance of radiological signs which indicates disease progression, and lack of diagnostic tools that indicate neonates with high risk of developing the disease as well (*Sharma and Hudak, 2013*).

Many studies has been carried out to investigate the most specific and sensitive tool for early detection of NEC.

Many non-invasive biomarkers are used to reflect the early steps of disease before the appearance of radiological changes for early diagnosis and intervention, One of the most promising biomarkers is urinary intestinal fatty acid binding protein u-IFABP that can detect early NEC with high sensitivity and specificity, Also the urinary level is correlated with the severity of the disease and length of bowel resected in NEC patients that needed surgical intervention (*Gregory et al., 2014*).

Urinary intestinal fatty acid binding protein (u-IFABP) is a small cytoplasmic protein with high organ sensitivity located in small intestinal enterocytes brush border involved in the uptake and transport of polar lipids. IFABP In the context of progressive gut wall barrier failure in NEC is released in the circulation with subsequent secretion by the kidneys. IFABP can be measured in serum and urine. An elevated urinary IFABP is a sensitive and specific non-invasive predictor of impending NEC 1day prior to the first clinical manifestation urinary iFABP screening might identify infants at high risk (*Golin et al., 2014*).

On the other hand a number of tools have been formulated to detect the risk for NEC development and facilitate interpersonal data interpretation, the most important is the GutCheck<sup>NEC</sup> tool which is formulated of ten items each of them reflects an independent risk factor for developing NEC, these factors are gestational age, NICU-specific NEC rate, black or Hispanic race, outborn status, multiple infections, metabolic acidosis, Packed red blood cell (RBC) transfusion, and two risk reducers: human milk fed at both day 7 and 14, intake of probiotics (*Gephart et al., 2013*).

GutCheck<sup>NEC</sup> score has underwent many stages of refinement to detect the most specific risk factors affecting NEC occurrence and prognosis and demonstrated very good (B-range) prediction for infants who developed surgical NEC and



those who died and (C-range) prediction of medical NEC (*Gephart 2012*).

The score is one of the most promising tools for early detection of the disease and still needs further studies and prospective clinical testing to confirm its sensitivity and specificity (*Gephart et al., 2014*).